The SAINT neuromodulation system is an FDA-approved, non-pharmacologic treatment for major depressive disorder. The SAINT system makes sense of complex brain imaging to identify the optimal spot in an individual’s brain to treat depression. Once identified, a precise, non-invasive pattern of magnetic stimulation is delivered in a condensed treatment protocol that reduces treatment time from weeks to days.
According to the U.S. National Institutes of Mental Health, major depression is one of the most common mental disorders in the U.S. Over 280 million people suffer from MDD globally, nearly half of whom have treatment-resistant depression, and far too many experience suicidal thoughts with no rapidly acting treatment options available.
In previous clinical trials, treatment with SAINT for MDD has resulted in a significant reduction in depressive symptoms at four weeks post-treatment following the five-day treatment protocol. Results from a double-blinded randomized controlled trial (RCT) evaluating SAINT were published in the American Journal of Psychiatry and demonstrate the SAINT approach has the promise to be a reproducible, rapid and effective treatment for severe, treatment-resistant depression.